Literature DB >> 3537452

Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis.

M G Bergeron, Y Marois.   

Abstract

The importance of high intrarenal levels of gentamicin on the outcome of experimental pyelonephritis was studied in rats receiving either a short course (three days) of gentamicin (G) alone or combined with a longer course (14 days) of ampicillin (A), cephalothin (C), or trimethoprim (T), or two weeks of therapy with ampicillin, cephalothin, trimethoprim and gentamicin given alone. While ampicillin, cephalothin and trimethoprim were undetectable in the medulla within six hours of cessation of therapy, gentamicin was still detectable in levels six folds above the MIC up to six months after treatment had ceased. Six months after the end of treatment, the percentage of sterile left kidneys in animals treated with ampicillin (50%), cephalothin (15%), trimethoprim (20%) was lower than the percentage of animals receiving 14 days of gentamicin (100%), or the combinations AG:89%, CG:67% and TG:60%, P less than 0.01. Following three days of gentamicin, 50% of the left kidneys were sterilized. When compared to ampicillin, cephalothin or trimethoprim alone, combined therapies significantly reduced the number of CFU in the kidneys P less than 0.01. These combinations were almost as effective as two weeks of therapy with gentamicin. Short-term therapy (three days) with an aminoglycoside which concentrates in the renal parenchyma, combined with an antibiotic which will accumulate in other parts of the nephron, may result in "pharmacological synergy". This new approach to therapy of pyelonephritis may be promising.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537452     DOI: 10.1038/ki.1986.211

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Pharmacologic Basis for the Treatment of Pyelonephritis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 2.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

3.  Autoradiographic study of tobramycin uptake by proximal and distal tubules of normal and pyelonephritic rats.

Authors:  M G Bergeron; Y Marois; C Kuehn; F J Silverblatt
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies.

Authors:  H Hvidberg; C Struve; K A Krogfelt; N Christensen; S N Rasmussen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 5.  Diagnosis and drug treatment of acute pyelonephritis.

Authors:  A Meyrier; J Guibert
Journal:  Drugs       Date:  1992-09       Impact factor: 9.546

6.  L-651,392, a potent leukotriene inhibitor, controls inflammatory process in Escherichia coli pyelonephritis.

Authors:  M Tardif; D Beauchamp; Y Bergeron; C Lessard; P Gourde; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Penetration of cefixime into fibrin clots and in vivo efficacy against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.

Authors:  M G Bergeron; A Turcotte
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.